Delay in treating age-related macular degeneration in Spain is associated with progressive vision loss

Arias, Luis; Armadá, Félix; Donate-López, J.; García‐Arumí, José; Giralt, J.; Pazos, B; Piñero, A.; Martínez, F.; Mondejar, José-Juan; Ortega, I; Zlateva, Gergana; Buggage, Ronald

doi:10.1038/sj.eye.6703053

Cited by 55 publications

(39 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Delays in diagnosis and treatment of NV-AMD increase the risk of progressive loss of visual function [6,7]. Because NV-AMD may significantly progress over a short period, further deterioration of visual function is to be expected shortly after the onset of initial symptoms.…”

Section: Discussionmentioning

confidence: 99%

“…The total duration of symptoms was not analysed in further detail. Arias et al [6] identified a mean secondary care interval of 2.3 months in patients with all forms of subfoveal CNV in AMD as part of a multicentre study in Spain. This value lies within the scale of our results.…”

Section: Discussionmentioning

confidence: 99%

“…Studies available so far from Canada and Europe usually refer to the time interval between symptom-related diagnosis, established by an ophthalmologist in a secondary care situation, and the definitive assessment of AMD by a retinal specialist within the frame of tertiary care. Thus these studies mostly cover the period of secondary and – at least partly – tertiary care [6,7,8]. …”

Section: Discussionmentioning

confidence: 99%

“…Delays in the run-up to tertiary care of patients with NV-AMD increase the risk for deterioration of visual acuity [2,6,7]. Efficacy and economic efficiency of new therapeutic approaches to NV-AMD are closely related to the shortest possible time interval between the onset of symptoms and the initiation of therapeutic procedures [8,9].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Time between Symptom Onset and Assessment in Age-Related Macular Degeneration with Subfoveal Choroidal Neovascularization

et al. 2009

View full text Add to dashboard Cite

Background: Therapy delay in neovascular age-related macular degeneration (NV-AMD) is associated with risk of visual deterioration. Methods: Retrospective cross section analysis including patients with NV-AMD who received fluorescein angiography (FA). The time elapsed from symptom onset to assessment was analysed in relation to different factors. Inclusion criteria were: age >50 years, symptom onset within 6 months before assessment, no previous AMD therapy, indication for vascular endothelial growth factor inhibitor treatment. Results: Mean duration of symptoms was 2.272 ± 1.683 months (n = 220); percentiles 25, 50, 75 and 90 corresponded to 1, 2, 3 and 5.383 months. A significant increase (p = 0.033) in mean symptom duration was found between age groups 65–74, 75–84 and over 84 years. Privately insured persons (assessment 1.242 ± 1.060 months after symptom onset; n = 14) received FA 1.083 months earlier (p = 0.0089) than patients with a statutory health insurance (assessment 2.325 ± 1.661 months after symptom onset; n = 194). Conclusion: In order to avoid progressive visual deterioration in patients with NV-AMD earlier assessment of these individuals should be aimed for.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Time between Symptom Onset and Assessment in Age-Related Macular Degeneration with Subfoveal Choroidal Neovascularization

et al. 2009

View full text Add to dashboard Cite

show abstract

“…Delays between detection and treatment are associated with more severe visual impairment. 36 However, visual acuity in new CNV patients usually remains near normal until the fovea is involved. Fifty-six percent of the eyes with subfoveal CNV and 80% of the eyes with non-subfoveal CNV have acuities $ 20/40.…”

Section: Prophylactic Treatmentmentioning

confidence: 99%

Improving patient outcomes: role of the primary care optometrist in the early diagnosis and management of age-related macular degeneration

Лю¹,

Swanson²

2013

OPTO

View full text Add to dashboard Cite

Not long ago, the management of age-related macular degeneration (AMD) was confined to rehabilitating whatever vision had not been damaged by the disease. The recent successes of the anti-vascular endothelial growth factor agents and the antioxidant clinical trials have revolutionized AMD treatment. For the first time, there is realistic hope that the progression of AMD can be slowed down or stopped and near normal vision can be preserved. Developments in new vision tests, imaging modalities, and genetic testing have greatly improved the chance of detecting the onset of AMD and choroidal neovascularization. However, because the current treatments still cannot revive degenerated retinal cells, the best patient outcome that can be achieved is early detection of the disease and application of the appropriate treatment before too much retinal damage has occurred. The opportunities and challenges offered by the new treatment options and disease detection methods have redefined the role of primary care optometrists in AMD management. This review of literature and practice guidelines demonstrates that, in addition to the traditional roles of refraction and visual rehabilitation, the unique position of optometrists as the first-line eye-care providers has allowed them to play an important role in the early detection of AMD, patient education, lifestyle-change counseling, disease monitoring and referral, and nutrition supplement counseling. The active participation of primary care optometrists in the shared care of AMD management is likely to result in great improvement in patient outcomes. Optometrists also need to improve their competence in these areas to meet the new challenges. Although primary care optometrists have always managed patients with AMD, their role in managing this sight-threatening disease has not been adequately documented. In light of the recent game-changing developments in AMD treatment, it is important to review what primary care optometrists are doing, what they can do, and what they should do to improve patient outcomes in the new era of AMD management. Keywords: detection, patient education, lifestyle-change counseling, disease monitoring, disease referral, nutrition supplement counseling Age-related macular degenerationAge-related macular degeneration (AMD) is an acquired degenerative disease of the macular area of the retina that, in its final stage, can cause severe visual impairment. AMD affects mainly older people and its prevalence increases with age. The prevalence of any AMD and late AMD (geographic atrophy [GA] or choroidal neovascularization [CNV]) in persons aged 40 years and older is between 5.2% and 14.3%, and between 0.3% and 2.6%, respectively, depending on race and ethnicity.1 AMD results in centrally located scotomas; reduced visual acuity, contrast sensitivity, color vision, and depth perception; and poor control of eye movements. AMD is one of the leading causes of severe visual impairment in Dovepress submit your manuscript | www.dovepress.com

show abstract

Gründe für Therapieverzögerung und -abbruch bei altersabhängiger Makuladegeneration

et al. 2017

View full text Add to dashboard Cite

show abstract

Delay in treating age-related macular degeneration in Spain is associated with progressive vision loss

Cited by 55 publications

References 20 publications

Time between Symptom Onset and Assessment in Age-Related Macular Degeneration with Subfoveal Choroidal Neovascularization

Time between Symptom Onset and Assessment in Age-Related Macular Degeneration with Subfoveal Choroidal Neovascularization

Improving patient outcomes: role of the primary care optometrist in the early diagnosis and management of age-related macular degeneration

Gründe für Therapieverzögerung und -abbruch bei altersabhängiger Makuladegeneration

Contact Info

Product

Resources

About